Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | CCKAR | P32238 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1147657 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6250394 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4620256 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL1147653 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL41664 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL5072556 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL344982 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6270543 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL246750 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL28166565 | 1.00 | HMGCR (0.98) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3649 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119951592-A | Preparation method of catalytic material for photocatalytic degradation of carbamazepine in sewage | 北方工业大学 | 2025-05-09 | — | — | CN | claimed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| CN-119185228-A | Fluvastatin sodium sustained release tablet and preparation method thereof | 杭州泓友医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-221999480-U | Purification device is used in fluvastatin sodium tablet production | 广州誉东健康制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| EP-4445959-A2 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | Catalent Ontario Limited (CA) | 2024-10-16 | — | — | EP | claimed |
| EP-3581173-B1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | CATALENT ONTARIO LTD (CA) | 2024-08-28 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-117860696-A | Fluvastatin sodium sustained release preparation and preparation method thereof | 浙江高跖医药科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-116924962-A | Preparation method of fluvastatin sodium impurity F | 广州瑞尔医药科技有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-4218765-A2 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG COA REDUCTASE INHIBITORS | NewAmsterdam Pharma B.V. (NL) | 2023-08-02 | — | — | EP | claimed |
| WO-2001056547-A2 | PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS | YOO SEO HONG (US) | 2001-08-09 | — | — | WO | claimed |
| US-6124340-A | FLUVASTATIN SODIUM FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | claimed |
| EP-0547000-B1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | NOVARTIS AG (CH) | 2000-02-02 | — | — | EP | claimed |
| EP-0907639-A1 | POLYMORPHIC COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-04-14 | — | — | EP | claimed |
| CN-1041794-C | Stabilized pharmaceutical compositions comprising an HMG-conreductase inhibitor compound | SANDOZ LTD (CH) | 1999-01-27 | — | — | CN | claimed |
| WO-1997049681-A1 | POLYMORPHIC COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1997-12-31 | — | — | WO | claimed |
| WO-1997026874-A1 | USE OF FLUVASTATIN DERIVATIVES IN SKIN DISEASE AND TOPICAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | claimed |
| US-5356896-A | Alkaline stabiling medium | SANDOZ LTD. (CH) | 1994-10-18 | — | — | US | claimed |
| CN-1091634-A | The stable pharmaceutical composition that contains a kind of β-Qiang Ji-β-Jia Jiwuersuandanxian coenzyme reductase inhibitor | SANDOZ LTD (CH) | 1994-09-07 | — | — | CN | claimed |
| EP-0547000-A1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | SANDOZ LTD. (CH) | 1993-06-16 | — | — | EP | claimed |